<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24236960</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>01</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-2277</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>27</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Transplant international : official journal of the European Society for Organ Transplantation</Title>
                <ISOAbbreviation>Transpl. Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ischemic postconditioning in human DCD kidney transplantation is feasible and appears safe.</ArticleTitle>
            <Pagination>
                <MedlinePgn>226-34</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/tri.12242</ELocationID>
            <Abstract>
                <AbstractText>Ischemic postconditioning may improve outcome after kidney transplantation. We performed a pilot study to assess feasibility and safety of ischemic postconditioning in human donation-after-circulatory-death kidney transplantation. Twenty patients were included. Primary outcome was rate of serious adverse events. Secondary outcomes were incidence of DGF and renal function at 3 months. Data were compared to a historical control group (n = 40). Furthermore, we performed a paired kidney analysis using the contralateral kidney (n = 11). Donor age and serum creatinine were higher in the experimental group compared with historical control: 57.7 (20-71) vs. 51.5 (24-74) years (P = 0.01) and 79 (40-156) μmol/l vs. 64 (25-115) μmol/l (P = 0.047). Postconditioning could be applied all times. One complication, a venous tear, occurred related to postconditioning. The experimental group experienced more DGF (85% vs. 63%) (P = 0.07). Serum creatinine at month 3 was 166 (109-331) μmol/l vs. 159 (81-279) μmol/l (P = 0.71). Paired kidney analysis showed no significant differences in DGF (72.2% vs. 54.5%, P = 0.66) and serum creatinine 199 (90-473) μmol/l vs. 184 (117-368) μmol/l (P = 0.76). This is the first report of applying IPoC in human kidney transplantation. Although IPoC is feasible and appears to be safe, no benefit in terms of reduced DGF or better renal function was observed (Dutch trial registry number NTR 3117).</AbstractText>
                <CopyrightInformation>© 2013 Steunstichting ESOT. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>van den Akker</LastName>
                    <ForeName>Eline K</ForeName>
                    <Initials>EK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, division of Transplant Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hesselink</LastName>
                    <ForeName>Dennis A</ForeName>
                    <Initials>DA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Manintveld</LastName>
                    <ForeName>Olivier C</ForeName>
                    <Initials>OC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lafranca</LastName>
                    <ForeName>Jeffrey A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Bruin</LastName>
                    <ForeName>Ron W F</ForeName>
                    <Initials>RW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weimar</LastName>
                    <ForeName>Willem</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ijzermans</LastName>
                    <ForeName>Jan N M</ForeName>
                    <Initials>JN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dor</LastName>
                    <ForeName>Frank J M F</ForeName>
                    <Initials>FJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Transpl Int</MedlineTA>
            <NlmUniqueID>8908516</NlmUniqueID>
            <ISSNLinking>0934-0874</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>AYI8EX34EU</RegistryNumber>
                <NameOfSubstance UI="D003404">Creatinine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057775" MajorTopicYN="N">Ischemic Postconditioning</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014019" MajorTopicYN="N">Tissue Donors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009927" MajorTopicYN="N">Tissue and Organ Procurement</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">DCD</Keyword>
            <Keyword MajorTopicYN="N">clinical trial</Keyword>
            <Keyword MajorTopicYN="N">feasibility</Keyword>
            <Keyword MajorTopicYN="N">human</Keyword>
            <Keyword MajorTopicYN="N">ischemic postconditioning</Keyword>
            <Keyword MajorTopicYN="N">kidney transplantation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>07</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>09</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24236960</ArticleId>
            <ArticleId IdType="doi">10.1111/tri.12242</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>